Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 4, Number 1—March 1998


Proteases of Malaria Parasites: New Targets for Chemotherapy

Philip J. RosenthalComments to Author 
Author affiliation: San Francisco General Hospital and University of California, San Francisco, California, USA

Main Article

Table 2

New antimalarial drugs

Drug Role Best Feature(s) Limitations
Halofantrine TX of Pf malaria; not approved for CP Usually effective against R Pf malaria Variable bioavailability, cardiac toxicity
Artemisinin and related compoundsa TX of Pf malaria Rapidly acting; effective against multidrug-R strains Recurrence after TX fairly common
Atovaquone ? TX of Pf malaria; ? CP (probably in combination with proguanil) Limited toxicity Limited studies so far show frequent recurrence after TX
Pyronaridinea ? TX of Pf malaria Effective against R strains Studies limited to date
Desferrioxamine ? TX of severe Pf malaria Well tolerated when used for iron overload Studies limited to date
Azithromycin ? CP Limited toxicity Studies limited to date

For abbreviations, see Table 1, footnote a.
aNot available in the United States.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO